Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inhaled SNG001 in hospitalized adults with moderate COVID-19
NL-OMON51111Phase 3Completed
- Sponsor
- Parexel
- Start
- Jun 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SNG001 with Placebo (2 arms). Primary endpoints: Time to hospital discharge and Time to recovery. Started Jun 2021; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51111.